Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms [0.03%]
Zhanqiang Zhang,Yue Wang,Haojun Zhang et al.
Zhanqiang Zhang et al.
Decitabine is widely used in the treatment of chronic myeloid neoplasms, potentially through its immunomodulatory effects on CD8+ T cells and natural killer (NK) cells. However, as decitabine is often administered in combination with other ...
Rare internal malignancies in xeroderma pigmentosum: A report of two cases from Tunisia and analysis of driver mutations [0.03%]
Soumaya Rammeh,Yasmine Ben Taher,Mariem Ben Rekaya et al.
Soumaya Rammeh et al.
Xeroderma pigmentosum (XP)-associated internal malignancies are characterized by their rarity, early onset, atypical histological presentations, and poorly characterized genomic landscape. In this study, we report the clinical, pathological...
Metabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as a potential therapeutic target [0.03%]
急性髓系白血病中的代谢途径和化疗耐药：烯酰辅酶a水合酶结构域含有的蛋白3的潜在治疗作用机制研究
Yijing Zhao,Hanfei Guo,Liting Niu et al.
Yijing Zhao et al.
Background: Acute myeloid leukemia (AML) is characterized by high relapse and mortality rates. Our previous investigation identified enoyl-CoA hydratase domain-containing protein 3 (ECHDC3) as being of prognostic signific...
Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer [0.03%]
赫二阳性乳腺癌新辅助曲妥珠单抗治疗的卫生经济学及疗效分析
Amirhossein Jalali,Shirin Moghaddam,Andrew McGuire et al.
Amirhossein Jalali et al.
Background: Globally, the incidence of breast cancer continues to rise; however, mortality rates are declining due to the growing effectiveness of targeted therapies and treatments. Overexpression of human epidermal growt...
Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study [0.03%]
靶向Glypican-3(GPC3)的嵌合抗原受体T细胞(JWATM204)治疗晚期肝细胞癌的安全性与有效性I期剂量递增研究
Yongqiang Yang,Jing Tang,Zilong Wu et al.
Yongqiang Yang et al.
Background: Glypican-3 (GPC3) is an important therapeutic target for chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma (HCC). JWATM204 is a novel GPC3-targeted CAR T cell therapy developed on the ...
Mushrooms as potent autophagy modulators in cancer therapy: Current evidence and therapeutic prospects [0.03%]
蘑菇作为癌症治疗中强大的自噬调节剂：现有证据和治疗前景
Md Mahmudul Hasan,Eva Azme,Rashedul Alam et al.
Md Mahmudul Hasan et al.
Mushrooms, recognized for their culinary and medicinal applications, are emerging as promising autophagy modulators in cancer therapy. Autophagy is cellular degradation triggered by organelle damage, protein aggregation, metabolic disturban...
Role of Ferredoxin 1 (FDX1) in cancer and its therapeutic potential [0.03%]
铁氧还蛋白1（FDX1）在癌症中的作用及其治疗潜力
Fen He,Hongyan Zhao,Ruixin Gao et al.
Fen He et al.
Ferredoxin 1 (FDX1) is a small iron-sulfur (Fe-S) cluster protein localized to the mitochondria. It functions as an electron carrier in diverse metabolic pathways and is critically involved in regulating protein lipoylation Accumulating evi...
Efficacy of chemotherapy combined with immunotherapy in advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations: A retrospective comparative study [0.03%]
表皮生长因子受体（EGFR）第20号外显子插入突变的晚期肺腺癌化疗联合免疫治疗疗效分析：一项回顾性比较研究
Ying Zhao,Xiujing Yao,Ruyue Li et al.
Ying Zhao et al.
Background: Although chemotherapy combined with immunotherapy is effective in advanced non-small cell lung cancer (NSCLC), its efficacy in patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) ...
Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD) [0.03%]
低剂量鲁索利替尼作为急性移植物抗宿主病的一线治疗会增加EB病毒再激活风险，但不会增加移植后淋巴增殖性疾病的风险
Kun Qian,Shuangyi Xing,Yujun Wei et al.
Kun Qian et al.
Background: Ruxolitinib (RUX) suppresses antiviral immunity in patients with hematologic diseases. For steroid-refractory acute graft-versus-host disease (aGVHD), studies have yielded conflicting results regarding whether...
The global landscape of particle beam radiotherapy trials over the past 15 years [0.03%]
过去15年粒子束放射治疗的临床试验格局分析
Wei Chen,Chenfei Wu,Mingying Xiao et al.
Wei Chen et al.
Background: Particle beam radiotherapy (PBRT), with its advantageous physical and biological properties, holds promise for improving therapeutic outcomes. To elucidate future clinical trial designs and policy decisions, w...